NICE green light for GSK’s Nucala
Final guidance on the drug’s use to treat patients with severe eosinophilic asthma on the NHS has now been published
Read More
Tag: eosinophilic asthma
NICE recommends Fasenra injection as asthma alternative
The National Institute for Health and Care Excellence (NICE) has recommended that a potentially life-changing treatment be available to people with a severe form of asthma on the NHS in England and Wales.
Read More
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment in patients with severe eosinophilic asthma.
Read More
NICE backs AZ’ asthma biologic Fasenra
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
Read More
AZ’ Fasenra gets US nod for eosinophilic asthma
AstraZeneca’s biologic Fasenra has picked up its first global approval in the US as a treatment for severe, eosinophilic asthma, a difficult to treat form of the condition.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
